The effect of these trends on long-term multidisciplinary management of obesity should be monitored to ensure patients can access both optimal pharmacologic and surgical treatment for obesity

Important considerations before combining these medications include: Absolute contraindications : The combination should be avoided in patients with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, during or within 14 days of MAOI use, personal/family history of MTC or MEN2, pregnancy, breastfeeding, or severe gastrointestinal disease Cardiovascular risk assessment : Phentermine increases heart rate and blood pressure, which requires careful monitoring with baseline and follow-up measurements of vital signs and possibly EKG if cardiac history exists Gastrointestinal tolerability : Tirzepatide commonly causes nausea, vomiting, and diarrhea, which may be compounded by phentermine's effects Medication interactions : Tirzepatide may reduce the effectiveness of oral contraceptives during initiation and dose escalation

In a 2023 trial of semaglutide in patients with obesity who did not have diabetes, Drucker noted prevention of cardiovascular events and death was seen as independent of weight loss
Among other benefits, GLP-1 is able to reduce blood glucose levels via insulin release, a highly desirable effect in patients with diabetes
This blend is commonly studied in experimental models where multiple peptide compounds are evaluated together to better understand overlapping or complementary pathway activity
Blood clots: Pain, discomfort, and redness in the affected area or unexplained pain in the arms, legs, or other parts of the body